BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

314 related articles for article (PubMed ID: 25841300)

  • 1. Saxagliptin is similar in glycaemic variability more effective in metabolic control than acarbose in aged type 2 diabetes inadequately controlled with metformin.
    Wang MM; Lin S; Chen YM; Shu J; Lu HY; Zhang YJ; Xie RY; Zeng LY; Mu PW
    Diabetes Res Clin Pract; 2015 Jun; 108(3):e67-70. PubMed ID: 25841300
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of baseline characteristics on glycemic effects of add-on saxagliptin or acarbose to metformin therapy: Subgroup analysis of the SMART study in Chinese patients with type 2 diabetes mellitus.
    Fang H; Xu F; Du J; Liang L; Li W; Shen L; Wang X; Xu C; Bian F; Mu Y
    J Diabetes Investig; 2020 Jul; 11(4):896-905. PubMed ID: 32020731
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A randomized controlled trial of the efficacy and safety of saxagliptin as add-on therapy in patients with type 2 diabetes and inadequate glycaemic control on metformin plus a sulphonylurea.
    Moses RG; Kalra S; Brook D; Sockler J; Monyak J; Visvanathan J; Montanaro M; Fisher SA
    Diabetes Obes Metab; 2014 May; 16(5):443-50. PubMed ID: 24205943
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Saxagliptin given in combination with metformin as initial therapy improves glycaemic control in patients with type 2 diabetes compared with either monotherapy: a randomized controlled trial.
    Jadzinsky M; Pfützner A; Paz-Pacheco E; Xu Z; Allen E; Chen R;
    Diabetes Obes Metab; 2009 Jun; 11(6):611-22. PubMed ID: 19515181
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Randomized, Double-Blind, Phase 3 Trial of Triple Therapy With Dapagliflozin Add-on to Saxagliptin Plus Metformin in Type 2 Diabetes.
    Mathieu C; Ranetti AE; Li D; Ekholm E; Cook W; Hirshberg B; Chen H; Hansen L; Iqbal N
    Diabetes Care; 2015 Nov; 38(11):2009-17. PubMed ID: 26246458
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and safety of saxagliptin compared with acarbose in Chinese patients with type 2 diabetes mellitus uncontrolled on metformin monotherapy: Results of a Phase IV open-label randomized controlled study (the SMART study).
    Du J; Liang L; Fang H; Xu F; Li W; Shen L; Wang X; Xu C; Bian F; Mu Y
    Diabetes Obes Metab; 2017 Nov; 19(11):1513-1520. PubMed ID: 28296055
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The efficacy and safety of saxagliptin when added to metformin therapy in patients with inadequately controlled type 2 diabetes with metformin alone.
    DeFronzo RA; Hissa MN; Garber AJ; Luiz Gross J; Yuyan Duan R; Ravichandran S; Chen RS;
    Diabetes Care; 2009 Sep; 32(9):1649-55. PubMed ID: 19478198
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of saxagliptin combination therapy in US patients with type 2 diabetes.
    Karyekar C; Donovan M; Allen E; Fleming D; Ravichandran S; Chen R
    Postgrad Med; 2011 Jul; 123(4):63-70. PubMed ID: 21680990
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Saxagliptin is non-inferior to glipizide in patients with type 2 diabetes mellitus inadequately controlled on metformin alone: a 52-week randomised controlled trial.
    Göke B; Gallwitz B; Eriksson J; Hellqvist A; Gause-Nilsson I;
    Int J Clin Pract; 2010 Nov; 64(12):1619-31. PubMed ID: 20846286
    [TBL] [Abstract][Full Text] [Related]  

  • 10. One-year efficacy and safety of saxagliptin add-on in patients receiving dapagliflozin and metformin.
    Matthaei S; Aggarwal N; Garcia-Hernandez P; Iqbal N; Chen H; Johnsson E; Chin A; Hansen L
    Diabetes Obes Metab; 2016 Nov; 18(11):1128-1133. PubMed ID: 27403645
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Randomized, Double-Blind Trial of Triple Therapy With Saxagliptin Add-on to Dapagliflozin Plus Metformin in Patients With Type 2 Diabetes.
    Matthaei S; Catrinoiu D; Celiński A; Ekholm E; Cook W; Hirshberg B; Chen H; Iqbal N; Hansen L
    Diabetes Care; 2015 Nov; 38(11):2018-24. PubMed ID: 26324329
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of saxagliptin in combination with metformin compared with sitagliptin in combination with metformin in adult patients with type 2 diabetes mellitus.
    Scheen AJ; Charpentier G; Ostgren CJ; Hellqvist A; Gause-Nilsson I
    Diabetes Metab Res Rev; 2010 Oct; 26(7):540-9. PubMed ID: 20824678
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Saxagliptin + metformin. Mostly disadvantages.
    Prescrire Int; 2013 Feb; 22(135):40. PubMed ID: 23444500
    [No Abstract]   [Full Text] [Related]  

  • 14. Initial combination therapy with saxagliptin and metformin provides sustained glycaemic control and is well tolerated for up to 76 weeks.
    Pfützner A; Paz-Pacheco E; Allen E; Frederich R; Chen R;
    Diabetes Obes Metab; 2011 Jun; 13(6):567-76. PubMed ID: 21342412
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term 4-year safety of saxagliptin in drug-naive and metformin-treated patients with Type 2 diabetes.
    Rosenstock J; Gross JL; Aguilar-Salinas C; Hissa M; Berglind N; Ravichandran S; Fleming D
    Diabet Med; 2013 Dec; 30(12):1472-6. PubMed ID: 23802840
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of saxagliptin added to metformin in Asian people with type 2 diabetes mellitus: a randomized controlled trial.
    Yang W; Pan CY; Tou C; Zhao J; Gause-Nilsson I
    Diabetes Res Clin Pract; 2011 Nov; 94(2):217-24. PubMed ID: 21871686
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of saxagliptin in combination with metformin as initial therapy in Chinese patients with type 2 diabetes: Results from the START study, a multicentre, randomized, double-blind, active-controlled, phase 3 trial.
    Dou J; Ma J; Liu J; Wang C; Johnsson E; Yao H; Zhao J; Pan C
    Diabetes Obes Metab; 2018 Mar; 20(3):590-598. PubMed ID: 28926170
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Saxagliptin add-on therapy in Chinese patients with type 2 diabetes inadequately controlled by insulin with or without metformin: Results from the SUPER study, a randomized, double-blind, placebo-controlled trial.
    Chen Y; Liu X; Li Q; Ma J; Lv X; Guo L; Wang C; Shi Y; Li Y; Johnsson E; Wang M; Zhao J; Ji L
    Diabetes Obes Metab; 2018 Apr; 20(4):1044-1049. PubMed ID: 29144061
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Saxagliptin and metformin XR combination therapy provides glycemic control over 24 hours in patients with T2DM inadequately controlled with metformin.
    Stenlöf K; Raz I; Neutel J; Ravichandran S; Berglind N; Chen R
    Curr Med Res Opin; 2010 Oct; 26(10):2355-63. PubMed ID: 20804445
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparative effect of saxagliptin and glimepiride with a composite endpoint of adequate glycaemic control without hypoglycaemia and without weight gain in patients uncontrolled with metformin therapy: Results from the SPECIFY study, a 48-week, multi-centre, randomized, controlled trial.
    Gu T; Ma J; Zhang Q; Zhu L; Zhang H; Xu L; Cheng J; Shi B; Li D; Shao J; Sun Z; Zhong S; Bi Y; Zhu D
    Diabetes Obes Metab; 2019 Apr; 21(4):939-948. PubMed ID: 30520221
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.